A portion of the US holdings for this investor are reported in this report and a portion are reported by other reporting manager(s). Top holdings included JUNO, DNLI, V, VOYA, and NTRS.
Filing 2017 Q4 compared to 2017 Q3 by default. Changes are calculated vs the previous SEC filing.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
Person Signing this Report on Behalf of Reporting Manager:
Name
Title
City, State
Date
John S. Cochran
Vice President
Fort Worth, Texas
14 Feb 2018
The number of shares in Juno Therapeutics Inc. reflected herein includes 248,330 shares over which Crestline Management, L.P. did not have investment discretion but which Douglas K. Bratton otherwise had ultimate investment discretion. Mr. Bratton also has ultimate investment discretion over Crestline Management, L.P. The number of shares in Denali Therapeutics Inc. reflected herein includes 1,111,798 shares held by Neuro Line Partners, L.P. over which Bratton Capital Management, L.P. and Bratton Capital, Inc. have investment discretion. Mr. Bratton has ultimate investment discretion over Bratton Capital Management, L.P., Bratton Capital, Inc. and Crestline Management, L.P.
List of Other Managers Reporting for Crestline Management, LP:
We use cookies and similar technologies to provide certain features, enhance
the user experience and deliver content that is relevant to your interests.
Depending on their purpose, analysis and marketing cookies may be used in
addition to technically necessary cookies. By clicking on "Agree and
continue", you declare your consent to the use of the aforementioned cookies.
Here
you can make detailed settings or revoke your consent (in part if necessary)
with effect for the future. For further information, please refer to our
Privacy Policy
.